ARTES Biotechnology: Press Releases
ARTES Steps Further into the Vaccine Business by Acquiring Anavax
ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines. ANAVAX is a patent-protected VLP technology that can be applied to...
Q Chip and ARTES Biotechnology Sign a Collaborative Agreement
Q Chip and ARTES Biotechnology have announced that they have signed a collaborative agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for...
ARTES and Rhein Minapharm Continue Their Successful Product Development Collaboration
ARTES Biotechnology, specialised in recombinant protein production and process development from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE,...
ARTES Becomes a Research Partner of the ChemBioTec Project Supported by Deutsche Stiftung Umwelt
ARTES Biotechnology has announced its collaboration with five other collaboration partners in a joint 28-month research programme that is granted by the national Deutsche Stiftung Umwelt within...
Exclusive Cooperation Between ARTES and the Ukrainian National Academy of Sciences
ARTES has announced that it has signed an exclusive marketing agreement with the Institute of Cell Biology of the National Academy of Science of Ukraine. The agreement is that the NAS...
ARTES Enters into a Partnership with Henkel for a Three-Year Research Programme
ARTES Biotechnology has announced its collaboration with Henkel in a joint three-year research programme that is granted by the German national BMBF (German Ministery of Education and...
ARTES and Minapharm Sign Long-Term Strategic Development Agreement
ARTES Biotechnology, which specializes in recombinant protein production from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm, jointly announced the start of...
Exclusive Cooperation Between ARTES and IPK
ARTES Biotechnology GmbH expands technology platform Having achieved notable success with the Hansenula technology for years, the biotech company ARTES has now concluded an exclusive...
Artes Enjoys Growing International Reputation
"We are looking forward to working with an international team“, says Dr Melanie Dröttboom, head of business development of Artes Biotechnology GmbH. Biotech company Artes, based...
New European Patent Granted
ARTES announces the grant of the European patent on increasing recombinant protein secretion in yeast by co-expression of Calnexin, a protein responsible in intracellular quality control...
PROTEO Biotech AG and ARTES Biotechnology GmbH: Strategic Alliance for Marketing of Elafin in Asia, Africa and South America
Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is...
ARTES Biotechnology GmbH and ProteoNic BV Start Research Collaboration
Today ARTES Biotechnology GmbH, Germany, and ProteoNic BV, The Netherlands, announced the start of their research collaboration. Both companies will join forces to investigate the application...
ARTES to present at BIOFINE, Barcelona and ACHEMA, Frankfurt
ARTES will present the technology and service offer plus the latest achievements and developments at: BIOFINE, Barcelona, on May 4th 2006 - 'Protein production using the Hansenula...
